Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells

KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) is an oncogenic driver with mutations in 30% of non-small cell lung cancer (NSCLC). However, there is no effective clinical drug even though it has been identified as an oncogene for 30 years. In this study, we identified a small molecule i...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Front Pharmacol
Prif Awduron: Xie, Chun, Li, Ying, Li, Lan-Lan, Fan, Xing-Xing, Wang, Yu-Wei, Wei, Chun-Li, Liu, Liang, Leung, Elaine Lai-Han, Yao, Xiao-Jun
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Frontiers Media S.A. 2017
Pynciau:
Pharmacology
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5694459/
https://ncbi.nlm.nih.gov/pubmed/29184501
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2017.00823
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg